While the prognostic value of driver mutations was limited, the risk of AML transition was higher in patients with at least one HMR mutation (i.e., ASXL1, EZH2, SRSF2, and IDH1/2) and further increased with two or more such mutations. This evidence concerns the gene EZH2 and acute myeloid leukemia.